Top

BMC Cancer

Published in:

Open Access 01-12-2015 | Research article

Network analysis of an in vitro model of androgen-resistance in prostate cancer

Authors: Sujitra Detchokul, Aparna Elangovan, Edmund J. Crampin, Melissa J. Davis, Albert G. Frauman

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

The development of androgen resistance is a major limitation to androgen deprivation treatment in prostate cancer. We have developed an in vitro model of androgen-resistance to characterise molecular changes occurring as androgen resistance evolves over time. Our aim is to understand biological network profiles of transcriptomic changes occurring during the transition to androgen-resistance and to validate these changes between our in vitro model and clinical datasets (paired samples before and after androgen-deprivation therapy of patients with advanced prostate cancer).

Methods

We established an androgen-independent subline from LNCaP cells by prolonged exposure to androgen-deprivation. We examined phenotypic profiles and performed RNA-sequencing. The reads generated were compared to human clinical samples and were analysed using differential expression, pathway analysis and protein-protein interaction networks.

Results

After 24 weeks of androgen-deprivation, LNCaP cells had increased proliferative and invasive behaviour compared to parental LNCaP, and its growth was no longer responsive to androgen. We identified key genes and pathways that overlap between our cell line and clinical RNA sequencing datasets and analysed the overlapping protein-protein interaction network that shared the same pattern of behaviour in both datasets. Mechanisms bypassing androgen receptor signalling pathways are significantly enriched. Several steroid hormone receptors are differentially expressed in both datasets. In particular, the progesterone receptor is significantly differentially expressed and is part of the interaction network disrupted in both datasets. Other signalling pathways commonly altered in prostate cancer, MAPK and PI3K-Akt pathways, are significantly enriched in both datasets.

Conclusions

The overlap between the human and cell-line differential expression profiles and protein networks was statistically significant showing that the cell-line model reproduces molecular patterns observed in clinical castrate resistant prostate cancer samples, making this cell line a useful tool in understanding castrate resistant prostate cancer. Pathway analysis revealed similar patterns of enriched pathways from differentially expressed genes of both human clinical and cell line datasets. Our analysis revealed several potential mechanisms and network interactions, including cooperative behaviours of other nuclear receptors, in particular the subfamily of steroid hormone receptors such as PGR and alteration to gene expression in both the MAPK and PI3K-Akt signalling pathways.

Available only for authorised users

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

AIHW. Australia’s health 2014. Canberra: AIHW2014 Contract No; 2014. Cat. no. AUS 178.

AIHW. Cancer in Australia: an overview 2012. Canberra: AIHW2012; 2012.

Huggins C, Hodges CV. Studies on prostatic cancer - I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1(4):293–7.

Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45. doi:10.1038/35094009.CrossRefPubMed

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate. 2010;70(5):457–66. doi:10.1002/pros.21079.PubMed

Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate. 2010;70(7):745–54. doi:10.1002/pros.21107.CrossRefPubMed

Xu G, Wu J, Zhou L, Chen B, Sun Z, Zhao F, et al. Characterization of the small RNA transcriptomes of androgen dependent and independent prostate cancer cell line by deep sequencing. PLoS ONE. 2010;5(11):e15519. doi:10.1371/journal.pone.0015519.CrossRefPubMedPubMedCentral

Takayama KI, Horie-Inoue K, Suzuki T, Urano T, Ikeda K, Fujimura T, et al. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer. Mol Endocrinol. 2012;26(5):748–61. doi:10.1210/me.2011-1242.CrossRefPubMed

10.

Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2013;66(1):32–9.CrossRefPubMed

11.

Thompson IM. Flare associated with LHRH-agonist therapy. Rev in urology. 2001;3 Suppl 3:S10–4.

12.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed

13.

Ang J, Fang BL, Ashman LK, Frauman AG. The migration and invasion of human prostate cancer cell lines involves CD151 expression. Oncol Rep. 2010;24(6):1593–7.PubMed

14.

Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562–78. doi:10.1038/nprot.2012.016.CrossRefPubMedPubMedCentral

15.

Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139–40. doi:10.1093/bioinformatics/btp616.CrossRefPubMed

16.

Cowley MJ, Pinese M, Kassahn KS, Waddell N, Pearson JV, Grimmond SM, et al. PINA v2.0: mining interactome modules. Nucleic Acids Res. 2012;40(Database issue):D862–5. doi:10.1093/nar/gkr967.CrossRefPubMed

17.

Huynh-Thu VA, Irrthum A, Wehenkel L, Geurts P. Inferring regulatory networks from expression data using tree-based methods. PLoS One. 2010;5(9). doi:10.1371/journal.pone.0012776.

18.

Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276–308. doi:10.1210/er.2002-0032.CrossRefPubMed

19.

Krause WC, Shafi AA, Nakka M, Weigel NL. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014;54:49–59. doi:10.1016/j.biocel.2014.06.013.CrossRefPubMedPubMedCentral

20.

Li Y, Vongsangnak W, Chen L, Shen B. Integrative analysis reveals disease-associated genes and biomarkers for prostate cancer progression. BMC Med Genet. 2014;7 Suppl 1:S3. doi:10.1186/1755-8794-7-s1-s3.

21.

Tang Y, Yan W, Chen J, Luo C, Kaipia A, Shen B. Identification of novel microRNA regulatory pathways associated with heterogeneous prostate cancer. BMC Syst Biol. 2013;7 Suppl 3:S6. doi:10.1186/1752-0509-7-s3-s6.CrossRefPubMedPubMedCentral

22.

Wang Y, Chen J, Li Q, Wang H, Liu G, Jing Q, et al. Identifying novel prostate cancer associated pathways based on integrative microarray data analysis. Comput Biol Chem. 2011;35(3):151–8. doi:10.1016/j.compbiolchem.2011.04.003.CrossRefPubMed

23.

Chen J, Wang Y, Shen B, Zhang D. Molecular signature of cancer at gene level or pathway level? Case studies of colorectal cancer and prostate cancer microarray data. Comput Math Methods Med. 2013;2013:909525. doi:10.1155/2013/909525.PubMedPubMedCentral

24.

Jiang J, Jia P, Zhao Z, Shen B. Key regulators in prostate cancer identified by co-expression module analysis. BMC Genomics. 2014;15:1015. doi:10.1186/1471-2164-15-1015.CrossRefPubMedPubMedCentral

25.

Madhamshettiwar P, Maetschke S, Davis M, Reverter A, Ragan M. Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets. Genome Med. 2012;4(5):41.CrossRefPubMedPubMedCentral

26.

Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9(8):537–49. doi:10.1038/nrc2694.CrossRefPubMed

27.

Lescarbeau RM, Kaplan DL. Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling. BMC Cancer. 2014;14:325. doi:10.1186/1471-2407-14-325.CrossRefPubMedPubMedCentral

28.

Rathkopf D, Scher HI. Androgen receptor antagonists in castration-resistant prostate cancer. Cancer J. 2013;19(1):43–9. doi:10.1097/PPO.0b013e318282635a.CrossRefPubMedPubMedCentral

29.

Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. 2000;7(2):211–47.CrossRefPubMed

30.

Zielinski AJ, Fong S, Allison J, Kawahara M, Coppe JP, Feiler H, et al. The helix-loop-helix Id-1 inhibits PSA expression in prostate cancer cells. Int J Cancer. 2010;126(10):2490–6. doi:10.1002/ijc.24811.PubMed

31.

Alimirah F, Chen J, Xin H, Choubey D. Androgen receptor auto-regulates its expression by a negative feedback loop through upregulation of IFI16 protein. FEBS Lett. 2006;580(6):1659–64. doi:10.1016/j.febslet.2006.02.015.CrossRefPubMed

32.

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67(3):470–9. doi:10.1016/j.eururo.2014.09.049.CrossRefPubMed

33.

Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev. 2006;58(4):685–704. doi:10.1124/pr.58.4.2.CrossRefPubMed

34.

Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update. 2000;6(3):225–36.CrossRefPubMed

35.

Beato M, Chavez S, Truss M. Transcriptional regulation by steroid hormones. Steroids. 1996;61(4):240–51.CrossRefPubMed

36.

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309–22. doi:10.1016/j.cell.2013.11.012.CrossRefPubMedPubMedCentral

37.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbo-Jorgensen C, et al. High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS ONE. 2015;10(2):e0116691. doi:10.1371/journal.pone.0116691.CrossRefPubMedPubMedCentral

38.

Latil A, Bieche I, Vidaud D, Lidereau R, Berthon P, Cussenot O, et al. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001;61(5):1919–26.PubMed

39.

Lau KM, Leav I, Ho SM. Rat estrogen receptor-alpha and -beta, and progesterone receptor mRNA expression in various prostatic lobes and microdissected normal and dysplastic epithelial tissues of the Noble rats. Endocrinology. 1998;139(1):424–7. doi:10.1210/endo.139.1.5809.PubMed

40.

Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma. Am J Pathol. 2001;159(1):79–92.CrossRefPubMedPubMedCentral

41.

Savoy RM, Ghosh PM. The changing roles of steroid nuclear receptors with prostate cancer progression. Endocr Relat Cancer. 2013;20(4):C9–11. doi:10.1530/erc-13-0193.CrossRefPubMed

42.

Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T, Deliveliotis C. Estrogen receptor (alpha and beta) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 2015;17(1):98–105. doi:10.4103/1008-682x.136445.CrossRefPubMed

43.

Zellweger T, Sturm S, Rey S, Zlobec I, Gsponer JR, Rentsch CA, et al. Estrogen receptor beta expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease. Endocr Relat Cancer. 2013;20(3):403–13. doi:10.1530/erc-12-0402.CrossRefPubMed

44.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study. Cancer Causes Control. 2011;22(8):1121–31. doi:10.1007/s10552-011-9787-7.CrossRefPubMedPubMedCentral

45.

Song CH, Lee HJ, Park E, Lee K. The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells. PLoS ONE. 2012;7(11):e49026. doi:10.1371/journal.pone.0049026.CrossRefPubMedPubMedCentral

46.

Cooney AJ, Tsai SY, O’Malley BW, Tsai MJ. Chicken ovalbumin upstream promoter transcription factor (COUP-TF) dimers bind to different GGTCA response elements, allowing COUP-TF to repress hormonal induction of the vitamin D3, thyroid hormone, and retinoic acid receptors. Mol Cell Biol. 1992;12(9):4153–63.CrossRefPubMedPubMedCentral

47.

Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA, Hilf R. Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. J Biol Chem. 1997;272(50):31465–74.CrossRefPubMed

48.

Shibata H, Nawaz Z, Tsai SY, O’Malley BW, Tsai MJ. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT). Mol Endocrinol. 1997;11(6):714–24. doi:10.1210/mend.11.6.0002.CrossRefPubMed

49.

Qin J, Wu SP, Creighton CJ, Dai F, Xie X, Cheng CM, et al. COUP-TFII inhibits TGF-beta-induced growth barrier to promote prostate tumorigenesis. Nature. 2013;493(7431):236–40. doi:10.1038/nature11674.CrossRefPubMed

50.

Tsai SY, Tsai MJ. Chick ovalbumin upstream promoter-transcription factors (COUP-TFs): coming of age. Endocr Rev. 1997;18(2):229–40. doi:10.1210/edrv.18.2.0294.PubMed

51.

Perets R, Kaplan T, Stein I, Hidas G, Tayeb S, Avraham E, et al. Genome-wide analysis of androgen receptor targets reveals COUP-TF1 as a novel player in human prostate cancer. PLoS ONE. 2012;7(10):e46467. doi:10.1371/journal.pone.0046467.CrossRefPubMedPubMedCentral

52.

Boudot A, Le Dily F, Pakdel F. Involvement of COUP-TFs in cancer progression. Cancers. 2011;3(1):700–15. doi:10.3390/cancers3010700.CrossRefPubMedPubMedCentral

53.

Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood. 1993;81(1):151–7.PubMed

54.

Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23(9):2078–93. doi:10.1200/jco.2005.02.047.CrossRefPubMed

55.

Jones E, Pu H, Kyprianou N. Targeting TGF-β in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets. 2009;13(2):227–34.CrossRefPubMed

56.

Zhu ML, Partin JV, Bruckheimer EM, Strup SE, Kyprianou N. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. Prostate. 2008;68(3):287–95. doi:10.1002/pros.20698.CrossRefPubMed

57.

van der Poel HG. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer. Eur Urol. 2005;48(6):1051–8. doi:10.1016/j.eururo.2005.09.006.CrossRefPubMed

58.

Matuszak EA, Kyprianou N. Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol & Metab. 2011;6(3):469–82. doi:10.1586/eem.11.32.CrossRef

59.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzym Regul. 2006;46:249–79. doi:10.1016/j.advenzreg.2006.01.004.CrossRef

60.

Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, et al. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer. 2005;12 Suppl 1:S99–111. doi:10.1677/erc.1.01005.CrossRefPubMed

61.

Zhang Y, Su H, Rahimi M, Tochihara R, Tang C. EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 2009;125(9):2021–8. doi:10.1002/ijc.24540.CrossRefPubMedPubMedCentral

62.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther. 2013;12(11):2342–55. doi:10.1158/1535-7163.mct-13-0032.CrossRefPubMed

63.

Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11(2 Pt 2):865s–70.PubMed

64.

Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, et al. Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget. 2015;6(2):604–16.CrossRefPubMed

65.

Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 2000;60(24):6841–5.PubMed

66.

Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012;41(2):425–32. doi:10.3892/ijo.2012.1487.PubMedPubMedCentral

67.

Trevino LS, Bingman WE, Edwards DP, Nl W. The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific. Steroids. 2013;78(6):542–7. doi:10.1016/j.steroids.2012.12.014.CrossRefPubMedPubMedCentral

68.

Boonyaratanakornkit V, Bi Y, Rudd M, Edwards DP. The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids. 2008;73(9–10):922–8. doi:10.1016/j.steroids.2008.01.010.CrossRefPubMed

69.

Skildum A, Faivre E, Lange CA. Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases. Mol Endocrinol. 2005;19(2):327–39. doi:10.1210/me.2004-0306.CrossRefPubMed

70.

Jiang J, Jia P, Shen B, Zhao Z. Top associated SNPs in prostate cancer are significantly enriched in cis-expression quantitative trait loci and at transcription factor binding sites. Oncotarget. 2014;5(15):6168–77.CrossRefPubMedPubMedCentral

71.

Chen T. Nuclear receptor drug discovery. Curr Opin Chem Biol. 2008;12(4):418–26. doi:10.1016/j.cbpa.2008.07.001.CrossRefPubMed

Title: Network analysis of an in vitro model of androgen-resistance in prostate cancer
Authors: Sujitra Detchokul
Aparna Elangovan
Edmund J. Crampin
Melissa J. Davis
Albert G. Frauman
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1884-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer

Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer

Diacerein retards cell growth of chondrosarcoma cells at the G2/M cell cycle checkpoint via cyclin B1/CDK1 and CDK2 downregulation

Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)

Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report

Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer